Midamaline | CAS#496-38-8 | Local Anesthetic

MedKoo Cat#: 535139 | Name: Midamaline

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Midamaline is a local anesthetic.

Chemical Structure

Midamaline

CAS#496-38-8

Theoretical Analysis

MedKoo Cat#: 535139

Name: Midamaline

CAS#: 496-38-8

Chemical Formula: C18H21ClN4

Exact Mass: 328.1455

Molecular Weight: 328.84

Elemental Analysis: C, 65.74; H, 6.44; Cl, 10.78; N, 17.04

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Midamaline

IUPAC/Chemical Name

N-(5-Chloro-2-benzimidazolylmethyl)-N-phenyl-N',N'-dimethylethylenediamine

InChi Key

VFSSTMGMWLZGCO-UHFFFAOYSA-N

InChi Code

InChI=1S/C18H21ClN4/c1-22(2)10-11-23(15-6-4-3-5-7-15)13-18-20-16-9-8-14(19)12-17(16)21-18/h3-9,12H,10-11,13H2,1-2H3,(H,20,21)

SMILES Code

CN(C)CCN(CC1=NC2=CC(Cl)=CC=C2N1)C3=CC=CC=C3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 328.84 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Schwarz RD, Callahan MJ, Coughenour LL, Dickerson MR, Kinsora JJ, Lipinski WJ, Raby CA, Spencer CJ, Tecle H. Milameline (CI-979/RU35926): a muscarinic receptor agonist with cognition-activating properties: biochemical and in vivo characterization. J Pharmacol Exp Ther. 1999 Nov;291(2):812-22. PMID: 10525104. 2: Trollor JN, Sachdev PS, Haindl W, Brodaty H, Wen W, Walker BM. Combined cerebral blood flow effects of a cholinergic agonist (milameline) and a verbal recognition task in early Alzheimer's disease. Psychiatry Clin Neurosci. 2006 Oct;60(5):616-25. doi: 10.1111/j.1440-1819.2006.01567.x. PMID: 16958947. 3: Jack CR Jr, Slomkowski M, Gracon S, Hoover TM, Felmlee JP, Stewart K, Xu Y, Shiung M, O'Brien PC, Cha R, Knopman D, Petersen RC. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology. 2003 Jan 28;60(2):253-60. doi: 10.1212/01.wnl.0000042480.86872.03. PMID: 12552040; PMCID: PMC2745302. 4: Zheng XM. Detecting regional cerebral blood flow changes in Alzheimer's patients after milameline treatment: activation or baseline SPECT? J Nucl Med Technol. 2002 Sep;30(3):118-22. PMID: 12186960. 5: Callahan MJ. Combining tacrine with milameline reverses a scopolamine-induced impairment of continuous performance in rhesus monkeys. Psychopharmacology (Berl). 1999 Jun;144(3):234-8. doi: 10.1007/s002130050998. PMID: 10435389. 6: Shah D, Blockx I, Guns PJ, De Deyn PP, Van Dam D, Jonckers E, Delgado Y Palacios R, Verhoye M, Van der Linden A. Acute modulation of the cholinergic system in the mouse brain detected by pharmacological resting-state functional MRI. Neuroimage. 2015 Apr 1;109:151-9. doi: 10.1016/j.neuroimage.2015.01.009. Epub 2015 Jan 9. PMID: 25583611. 7: Hartvig P, Nordberg A, Torstenson R, Sjöberg P, Fasth KJ, Långström B. Interaction of a muscarinic cholinergic agonist on acetylcholine and dopamine receptors in the monkey brain studied with positron emission tomography. Dement Geriatr Cogn Disord. 2002;13(4):199-204. doi: 10.1159/000057697. PMID: 12006729. 8: Wood MD, Murkitt KL, Ho M, Watson JM, Brown F, Hunter AJ, Middlemiss DN. Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry. Br J Pharmacol. 1999 Apr;126(7):1620-4. doi: 10.1038/sj.bjp.0702463. PMID: 10323594; PMCID: PMC1565933. 9: Bymaster FP, Carter PA, Peters SC, Zhang W, Ward JS, Mitch CH, Calligaro DO, Whitesitt CA, DeLapp N, Shannon HE, Rimvall K, Jeppesen L, Sheardown MJ, Fink- Jensen A, Sauerberg P. Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects. Brain Res. 1998 Jun 8;795(1-2):179-90. doi: 10.1016/s0006-8993(98)00267-4. PMID: 9622623. 10: Shannon HE, Hart JC, Bymaster FP, Calligaro DO, DeLapp NW, Mitch CH, Ward JS, Fink-Jensen A, Sauerberg P, Jeppesen L, Sheardown MJ, Swedberg MD. Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats. J Pharmacol Exp Ther. 1999 Aug;290(2):901-7. PMID: 10411607. 11: Watson JM, Hunter AJ, Brown AM, Middlemiss DN. In vitro characterisation of the muscarinic receptor partial agonist, sabcomeline, in rat cortical and heart membranes. Eur J Pharmacol. 1999 Apr 1;370(1):69-77. doi: 10.1016/s0014-2999(99)00081-3. PMID: 10323282. 12: Heidrich A, Rösler M, Riederer P. Pharmakotherapie bei Alzheimer-Demenz: Therapie kognitiver Symptome--neue Studienresultate [Pharmacotherapy of Alzheimer dementia: therapy of cognitive symptoms--new results of clinical studies]. Fortschr Neurol Psychiatr. 1997 Mar;65(3):108-21. German. doi: 10.1055/s-2007-996315. PMID: 9173033. 13: Jones CK, Eberle EL, Shaw DB, McKinzie DL, Shannon HE. Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats. J Pharmacol Exp Ther. 2005 Mar;312(3):1055-63. doi: 10.1124/jpet.104.075887. Epub 2004 Dec 1. PMID: 15574685. 14: Rockwood K, Strang D, MacKnight C, Downer R, Morris JC. Interrater reliability of the Clinical Dementia Rating in a multicenter trial. J Am Geriatr Soc. 2000 May;48(5):558-9. doi: 10.1111/j.1532-5415.2000.tb05004.x. PMID: 10811551. 15: Palacios JM. Alzheimer's disease: new pharmacological perspectives. Methods Find Exp Clin Pharmacol. 1996;18 Suppl B:67-8. PMID: 8899698. 16: Rosin A, Kitchen I, Georgieva J. Effects of single and dual administration of cocaine and ethanol on opioid and ORL1 receptor expression in rat CNS: an autoradiographic study. Brain Res. 2003 Jul 18;978(1-2):1-13. doi: 10.1016/s0006-8993(03)02674-x. PMID: 12834892. 17: Sramek JJ, Sedman AJ, Reece PA, Hourani J, Bockbrader H, Cutler NR. Safety and tolerability of CI-979 in patients with Alzheimer's disease. Life Sci. 1995;57(5):503-10. doi: 10.1016/0024-3205(95)00283-c. PMID: 7623616. 18: Dethloff LA, Chang T, Courtney CL. Toxicological comparison of a muscarinic agonist given to rats by gavage or in the diet. Food Chem Toxicol. 1996 Apr;34(4):407-22. doi: 10.1016/0278-6915(96)00128-7. PMID: 8641667. 19: Cutler NR, Sramek JJ. Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study. Eur J Clin Pharmacol. 1995;48(6):421-8. doi: 10.1007/BF00194329. PMID: 8582458. 20: Sedman AJ, Bockbrader H, Schwarz RD. Preclinical and phase 1 clinical characterization of CI-979/RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease. Life Sci. 1995;56(11-12):877-82. doi: 10.1016/0024-3205(95)00023-y. PMID: 10188788.